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sion of ECM markers, collagen synthesis, or TGF-  could be 
observed after BTA treatment of keloid fibroblasts. In addi-
tion, cell proliferation and metabolism of keloid fibroblasts 
was not affected by BTA treatment.  Conclusion: The sug-
gested clinical efficiency of intralesional BTA for the therapy 
of existent keloids could not be confirmed in this study. 
Based on our data, the potential mechanisms of action of 
BTA on keloid-derived fibroblasts remain unclear. 
 Copyright © 2012 S. Karger AG, Basel 
 Introduction 
 In skin, scars form as the result of a complex physio-
logic wound healing cascade and may arise following
any insult to the deeper dermis  [1] . Hypertrophic scars 
(HS) and keloids are the pathological results of excessive 
scarring and – in addition to their poor aesthetic appear-
ance – are often associated with clinical symptoms such 
as itching, pain, and increased rigidity. Aberrations in the 
wound healing process promote HS and keloid forma-
tion, and an imbalance between anabolic and catabolic 
phases during wound closure is possibly relevant. Further 
risk factors for pathologic scars include genetic suscepti-
bility, localization in specific anatomic sites, prolonged 
inflammation, wound infections, and delayed epitheli-
alization  [1] . Compared to HS, keloids appear to be the 
result of a more sustained and aggressive fibrotic process 
 [2] . Current evidence points to a more prolonged inflam-
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 Abstract 
 Introduction: Keloids are the result of excessive scar tissue 
formation. Besides their poor aesthetic appearance, keloids 
can be associated with severe clinical symptoms such as 
pain, itching, and rigidity. Unfortunately, most therapeutic 
approaches remain clinically unsatisfactory. Recently, injec-
tions with botulinum toxin A (BTA) were proposed for the 
treatment of established keloids in a clinical trial. In this 
study, we aimed to verify the effects of intralesional BTA for 
the treatment of therapy-resistant keloids using objective 
measurements. In addition, the underlying molecular mech-
anisms were investigated using cultured keloid-derived fi-
broblasts.  Materials and Methods: Four patients received 
BTA (doses varying from 70 to 140 Speywood units per ses-
sion) injected directly into their keloids every 2 months for 
up to 6 months. Differences in height and volume were eval-
uated clinically and measured with a 3-D optical profiling 
system. Keloid-derived fibroblasts were treated with differ-
ent concentrations of BTA, and expression of collagen 
(COL)1A1, COL1A2, COL3A1, TGF-  1, TGF-  2, TGF-  3, fibro-
nectin-1, laminin-  2, and   -SMA was determined by real-
time quantitative PCR. MTT and BrdU assays were used to 
analyze the effects of BTA on fibroblast proliferation and me-
tabolism.  Results: Intralesional administration of BTA did not 
result in regression of keloid tissue. No differences in expres-
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matory period with a specific immune cell infiltrate pres-
ent in the scar tissue of keloids resulting in increased fi-
broblast activity with greater and more sustained extra-
cellular matrix (ECM) deposition  [2] .
 In the developed world alone, a total of 100 million 
patients develop scars each year as a result of 55 million 
elective surgeries and 25 million operations after acci-
dental trauma  [3] . A recent survey performed in the USA 
confirmed that many patients are disappointed with the 
resulting scars irrespective of gender, age, or ethnicity  [4] . 
As demonstrated in this survey, many patients would 
highly value any opportunity to improve or minimize 
scarring following surgery or trauma  [4] . However, most 
therapeutic approaches remain clinically unsatisfactory, 
probably due to poor knowledge of the complex mecha-
nisms underlying the process of excessive scarring.
 Reduction of the muscular tensile force during scar 
formation as well as restoration of the balance between 
fibroblast proliferation and cellular apoptosis may rep-
resent a novel therapeutic option for the aesthetic im-
provement of postsurgical scars  [5] . Botulinum toxin A 
(BTA) paralyzes local muscles and reduces skin tension 
caused by muscle pull, thereby decreasing scar tension 
and subsequent inflammation in wound edges  [6] . In-
deed, Gassner et al.  [7] could demonstrate that BTA in-
jections into the musculature adjacent to the wound 
within 24 h of wound closure resulted in enhanced 
wound healing and less noticeable scars compared to 
placebo. Recently, intralesional injections with BTA 
were also proposed for the treatment of established ke-
loids in a prospective, uncontrolled study  [8] . BTA was 
injected into the lesions at 3-month intervals for a max-
imum of 9 months at a concentration of 35 units/ml. 
Total doses ranged from 70 to 140 units per session. At 
the 1-year follow up, three of the 12 included patients 
demonstrated excellent results, 5 patients had good re-
sults, and 4 patients had fair results. This therapy did not 
fail in any of the patients. When analyzing clinical 
symptoms, scar regression was noted from the periph-
ery in all of the patients, followed by flattening of the 
lesions. Within the follow-up period of 1 year, no signs 
of recurrence were noted in any of the patients. As a 
mechanism, the same group could then demonstrate 
that BTA was able to reduce the expression of TGF-  1 
protein in fibroblasts derived from scars and signifi-
cantly reduced their proliferating rate  [9] .
 As BTA promised to be very effective in the treatment 
of pathologic scars, this study aimed to verify the effects 
of intralesional BTA on keloids resistant to any previous 
therapy using objective measurements. In addition, the 
potential underlying molecular mechanisms of BTA 
treatment on keloid tissue were investigated using cul-
tured keloid-derived fibroblasts.
 Material and Methods 
 Patients 
 Four patients (2 male, 2 female) suffering from keloids for lon-
ger than 2 years resistant to any previous therapy (e.g. kryothera-
py, intralesional corticosteroids, silicone sheets) and presenting to 
the scar clinic of the Department of Dermatology and Allergy, 
Ludwig Maximilian University, Munich, from May to July 2011, 
were included in the present study after signing informed consent 
forms. Keloid scars were defined clinically as itchy, raised, ery-
thematous tumors projecting beyond the original wound mar-
gins. A detailed patient history including duration, any predis-
posing factors such as trauma, infection, or any inflammatory 
skin disorder, any prior treatment implemented, and family his-
tory was obtained. In all 4 patients, any prior treatment was dis-
continued for at least 6 months before starting treatment with 
intralesional BTA. For treatment, BTA (Azzalure, 125 Speywood 
units diluted in 0.5 ml saline) in a total dose varying from 70 to 
140 Speywood units per session was injected directly into the ke-
loid tissue every two months using a 24-gauge needle for a maxi-
mum of 6 months.
 3-D Optical Profiling 
 3-D optical profiling (Primos 3D Imaging; GFMesstechnik 
GmbH, Vectra 3D) was used to objectively measure the differ-
ences in height of the keloid scars at baseline and after 2–4 treat-
ment sessions.
 Fibroblast Culture and BTA Treatment 
 Primary fibroblasts were isolated from tissue biopsies ob-
tained from keloids from 3 independent patients after signing in-
formed consent. Different patients with keloids were chosen for 
fibroblast isolation as an additional, partial keloid excision for fi-
broblast isolation could have negatively influenced the outcome 
of BTA treatment. However, keloids chosen for fibroblast isolation 
were comparable to those that were treated with BTA injections 
with respect to body location and the skin color of the respective 
patients. First, subcutaneous fat was removed from keloid speci-
mens and washed in PBS. For separation of the dermis, specimens 
were incubated overnight at 4  °  C in sterile Dispase II (Roche) so-
lution (4 mg/ml). The next day the epidermis was detracted and 
the dermis was minced into pieces of 2 mm 2 in sterile cell culture 
dishes. Explants were gently covered with Dulbecco’s modified 
Eagle’s medium (PAA Laboratories) supplemented with 10% fetal 
bovine serum and penicillin (100 U/ml), and streptomycin (100 
  g/ml) (PAA Laboratories), and incubated in a humidified incu-
bator at 37  °  C and 5% CO 2 . Fibroblasts were grown out of the tis-
sue and after 3–4 weeks cells were detached by trypsin and re-
plated. Passages 3–6 of keloid-derived fibroblasts were seeded at 
a density of 1  ! 104 cells in 12-well plates. After 48 h, the cells 
were placed in serum-free medium for at least 24 h before starting 
the experiments. Medium was changed to DMEM with 1% fetal 
bovine serum, and BTA (Azzalure, 5–10 U/ml) was added to cul-
tured cells for different time periods.
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 Real-Time Quantitative RT-PCR 
 For gene expression analyses cells were harvested after 24 h 
and total RNA was isolated using an RNA Miniprep Kit (Zymo 
Research). cDNA synthesis was performed with 1 ug of total RNA 
using a DyNAmo cDNA Synthesis Kit (Finnzymes). Expression 
of collagen (COL)1A1, COL1A2 and COL3A1, TGF-  1, TGF-  2, 
TGF-  3, fibronectin-1, laminin-  2,   -SMA, and PCNA (prolif-
erating cell nuclear antigen) was determined by quantitative PCR 
(qPCR) using Evagreen PCR Master Mix (BioRad) as specified by 
the manufacturer. All primers were synthesized by Qiagen, and 
  -actin was used as housekeeping gene for normalization. All 
PCR assays were run in the Bio Rad CFX96 Real-Time System.
 Cell Proliferation Assays 
 Fibroblast proliferation was determined by BrdU assay (Roche 
Applied Science). Cells were incubated with BTA for 72 h and 
BrdU added to the cell culture for the final 24 h. Incoporated BrdU 
was then detected by an anti-BrdU antibody labeled with HRP. 
Absorbance was measured at 370 nm using a microplate reader.
 The MTT assay was performed using an MTT cell prolifera-
tion kit (R&D Systems). After 72 h of incubation with different 
concentrations of BTA, 30   l of MTT reagent were added to the 
medium and the cells were incubated for another 4 h at 37  °  C. Af-
ter addition of the solubilization solution, absorption of the pro-
duced formazan was measured at 570 nm.
 Data Analysis 
 All graphs and statistical calculations were made using Graph-
Pad Prism 5.0 (GraphPad Software, Inc.) Statistical differences 
between groups were determined using a two- or one-tailed Stu-
dent’s t test. Values are expressed as means  8 SD and p  ! 0.05 was 
considered statistically significant.
 Results 
 Repeated injections with BTA for up to 6 months did 
not change the macroscopic appearance, morphology, or 
size of keloid scars in 4 patients ( fig. 1 a). Objective mea-
surements using optical profilometry confirmed the vi-
sual impression and confirmed no significant change in 
keloid volume and height after BTA therapy ( fig. 1 b–d).
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 Fig. 1. BTA shows no effect on keloid appearance in vivo. BTA 
(Azzalure, 125 Speywood units diluted in 0.5 ml saline) was in-
jected directly into the keloid tissue every 2 months using a 
24-gauge needle for a maximum of 6 months. The clinical course 
was monitored ( a ) and keloids were analyzed by 3-D optical pro-
filing. Color-coded surface topography images of one representa-
tive keloid at baseline and 2 months after the last injection, as well 
as differences in scar height, are displayed in  b and  c . The chang-
es in volume (V erh ) of 4 patients are summarized in  d (mean  8 
SD). 
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 Fig. 2. BTA shows no effect on keloid-derived fibroblasts. Isolated 
primary fibroblasts from keloid patients (n = 3) were cultured and 
treated with BTA in increasing concentrations. mRNA abun-
dance of TGF-  1–3, COL1A1, COL1A2, COL3A1, fibronectin 1, 
laminin-  2,   -SMA, and PCNA was determined by real-time 
qPCR after 24 h ( a–d ). Cell proliferation was analyzed using a 
BrdU assay and cell metabolism was measured with an MTT assay 
( e ,  f ). Values are expressed as means  8 SD from representative 
experiments performed in triplicate. 
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 In cultured fibroblasts isolated from keloid scars BTA 
treatment did not change the expression of TGF-  1–3, 
COL1A1, COL1A2, or COL3A1 ( fig. 2 a, b). Also, the tran-
scriptional activity of genes involved in the synthesis of 
ECM proteins which are excessively activated in keloid 
scars such as fibronectin 1, laminin-  2, and   -SMA was 
unchanged after BTA treatment ( fig. 2 c).
 Consistent with the macroscopic impression that the 
cell proliferation of keloid fibroblasts was unchanged af-
ter BTA treatment, the expression of the proliferation 
marker PCNA remained unchanged after BTA therapy 
( fig. 2 d).
 These observations were confirmed in BrdU and MTA 
assays demonstrating that keloid fibroblasts treated with 
BTA show similar proliferative and metabolic activity 
when compared to control treated cells ( fig. 2 e, f).
 Discussion 
 Currently, successful treatment of keloids remains dif-
ficult. As a consequence, both clinicians and their pa-
tients value even the smallest improvements in the ap-
pearance of those pathologic scars after treatment. In
an effort to successfully treat keloids, various novel ap-
proaches have been introduced in recent years including 
various laser techniques, intralesional 5-FU, interferon 
injections, or topically applied imiquimod (to name a 
few)  [10] . Very recently, the use of BTA was suggested to 
extend the spectrum of treatment for excessive scars. 
Xiao et al.  [11] studied 19 patients suffering from HS who 
received intralesional injections of BTA (2.5 units/ml at 
1-month intervals, exact substance unknown) for a total 
of 3 months. At a 6-month follow up, all patients present-
ed with clinical improvement of their scars resulting in 
high subjective satisfaction. Clinical symptoms such as 
erythema, pruritus, and a pliability score decreased sig-
nificantly after BTA injections when compared to base-
line  [11] . In another prospective, uncontrolled study,
Zhibo et al.  [8] demonstrated that BTA injected into 12 
keloids (70–140 units per session every 3 months, exact 
substance unknown) resulted in significant improve-
ment of the treated scar at a 1-year follow up. In this study 
none of the patients showed failure of therapy.
 At present, the effect of many therapies used for exces-
sive scars has never been tested in clinical trials. Only a 
few therapeutic modalities have been shown to be effec-
tive in well-designed prospective studies with adequate 
control groups. As the reported results for BTA treatment 
for excessive scars are very promising, we attempted to 
elucidate the potential beneficial effects of BTA on scar 
appearance in an objective manner. A three-dimensional 
optical profiling system was employed to measure de-
creases in scar height and volume after BTA treatment. 
Measurements were taken at baseline and 3 months after 
the final injection. The Primos 3D imaging system proj-
ects light onto a specific surface of the skin and records 
the image with a CCD camera. Skin surface micro-topog-
raphy is reconstructed using temporal phase shift algo-
rithms to generate 3-D images  [12] . Subsequently, an in-
traindividual comparison between baseline and later 
time points is made and any subjective influences on scar 
evaluation can be avoided. Nevertheless, objective evalu-
ation of BTA-treated keloids using optical profilometry 
confirmed the macroscopic assessment and no signifi-
cant changes after BTA therapy compared to baseline 
could be detected in our patients. Although we treated a 
relatively small number of patients and used different 
doses of BTA, at least a slight improvement in scar height 
or volume should have been noted if BTA is as effective 
in reducing scar height as previously described  [8, 11] . 
Thus, based on those observations, the suggested clinical 
efficiency of intra-lesional BTA for the treatment of exis-
tent keloids remains uncertain.
 Doubtless, due to poor understanding of the complex 
molecular mechanisms underlying the process of exces-
sive scarring, most therapeutic approaches remain unsat-
isfactory  [1] . Excessive scar tissue formation results from 
increased deposition of large amounts of ECM in the der-
mis  [13] . Pathologic scars are densely populated by fibro-
blasts and inflammatory cells which maintain a fibro-
genic micro milieu by secreting TGF-  and other cyto-
kines  [14] . Increased production of collagen, proteogly-
cans, and fibronectin, deficient ECM degradation, and 
remodeling are the consequences  [2] . Current research in 
keloid pathophysiology further suggests that alterations 
of the fibroblast phenotype by several growth factors and 
downstream signaling pathways are involved in the 
pathogenesis of excessive scar formation  [15] . In particu-
lar, TGF-  cytokines and downstream smad pathways 
are key regulators in early stages of normal scar and/or 
keloid formation. While TGF-  1 and TGF-  2 represent 
the most important stimulators of collagen and proteo-
glycan synthesis, administration of TGF-  3 reduces con-
nective tissue deposition  [16–18] . Effects on those signal-
ing mediators could be responsible for the proposed effect 
of BTA on excessive scars. Indeed, a recent in vitro study 
by Xiao et al.  [9] reported that BTA may exert its benefi-
cial effects on excessive scar appearance by inhibiting the 
proliferation of fibroblasts and by decreasing the levels of 
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TGF-  1. In order to investigate the potential underlying 
molecular mechanisms of BTA treatment on keloid tis-
sue, we incubated keloid-derived fibroblasts with differ-
ent concentrations of BTA and the expression of various 
factors known to be involved in excessive scar formation 
were determined. However, no differences in expression 
ECM markers such as fibronectin-1, laminin-  2, or   -
SMA, markers for collagen synthesis or TGF-  1, TGF-
  2, and TGF-  3 proteins could be observed in keloid-
derived fibroblasts after BTA treatment. Also, no differ-
ences in the proliferative and metabolic activity of keloid-
derived fibroblasts after BTA incubation were detected 
when compared to nontreated cells.
 Thus, while reduction of the tensile force by prophy-
lactic BTA injections into the musculature adjacent to the 
respective wound during the course of wound healing 
and scar formation might represent a comprehensible 
mechanism of action for aesthetic improvement of post-
surgical scars, the proposed mechanisms of action of 
BTA on existing keloids as suggested elsewhere remain 
unclear  [9] . Certainly, more in-depth studies on the in 
vitro and in vivo effects of BTA on pathologic scars and/
or mature keloids are needed before a comparatively ex-
pensive therapy for this particular indication can be pos-
tulated. Also, distinct factors such as genetic background, 
race, the phase of keloid development, and the location of 
the pathologic scar could have an impact on the success 
of this proposed treatment method. 
